2 active not recruiting. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Cardiogenic Shock: new trials by email Literature Review of Cardiogenic Shock trials Research Report on Cardiogenic Shock
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| Low-Dose Dobutamine and Single-Dose Tocilizumab in Acute Myocardial Infarction With High Risk of Cardiogenic Shock Tocilizumab, Dobutamine, NaCl 0.9% - Acute Myocardial Infarction, Cardiogenic Shock | Phase 2 | Active not recruiting | Copenhagen University Hospital, Rigshospitalet | 100 | 2022-03-13 | 2025-07-17 |
Shock, Cardiogenic (2) · Inflammation (1) · ST Elevation Myocardial Infarction (1)
Cardiovascular Diseases (2) · Heart Diseases (2) · Infarction (2) · Ischemia (2) · Myocardial Infarction (2) · Myocardial Ischemia (2) · Necrosis (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Shock (2) · Vascular Diseases (2)
Dobutamine (1) · Istaroxime (1) · Lactic Acid (1) · Sodium Chloride (1) · tocilizumab (1)
Copenhagen University Hospital, Rigshospitalet (1) · Windtree Therapeutics (1)
Argentina (1) · Denmark (1) · Israel (1) · Italy (1) · Poland (1) · United States (1)